Slingshot members are tracking this event:

Arrowhead Pharma (ARWR) to Release Top-Line Results in 2016 From Expanded Part A and Part B of Phase 1 Trial Evaluating ARC-AAT in Liver Disease Associated With a Rare Genetic Disorder Causing Alpha-1 Antitrypsin Deficiency (AATD)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Top-line Results, Expanded Part A And Part B, Phase 1 Trial Results, Arc-aat, Alpha-1 Antitrypsin Deficiency